Alzamend Neuro ALZN
NASDAQ ALZN
$1.25 +0.00 (+0.00%)
As of: Oct 22, 2026 · 9:30 AM EDT

Alzamend Neuro (ALZN) Preferred Stock Liabilities (2024)

Updated

Alzamend Neuro (ALZN) posted Preferred Stock Liabilities of $477,737 for fiscal Q3 2024 (quarter ended Jan 31, 2024).

Analysis

Alzamend Neuro (ALZN) Preferred Stock Liabilities (2024) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Eli Lilly 1,166.12 Bn 1,134.70 Bn 19.71 Bn -
2 Johnson & Johnson 634.67 Bn 553.20 Bn 17.26 Bn -
3 AbbVie 503.03 Bn 476.14 Bn 12.70 Bn -
4 Merck 377.66 Bn 332.04 Bn 12.21 Bn -
5 Novartis Ag 303.82 Bn 267.81 Bn 11.24 Bn -
6 Astrazeneca 266.80 Bn 240.49 Bn 12.86 Bn -
7 Amgen 240.87 Bn 196.27 Bn 7.24 Bn -
8 Gilead Sciences 193.45 Bn 167.65 Bn 6.22 Bn -
9 Pfizer 172.20 Bn 118.84 Bn 10.94 Bn -
10 Alzamend Neuro 5.60 Mn -9.87 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jan 31, 2024 477,737.00
API Access

Alzamend Neuro Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=ALZN&period=max&api_key=YOUR_API_KEY